In the last six years, a tool called CRISPR-Cas9 has transformed genetic research, allowing scientists to snip and edit DNA strands at precise locations like a pair of tiny scissors.
But sometimes, it takes more than scissors to do the job.
Now, a collaborative international team has unveiled a new CRISPR-based tool that acts more like a DNA shredder, wiping out long stretches of DNA in human cells with programmable targeting.
Writing in Molecular Cell, the team describes how it succeeded in getting a different kind of CRISPR-Cas system called Type I CRISPR-Cas3 to work as a long-range DNA editing tool in human cells for the first time.
The resulting tool provides a way to target and delete much longer expanses of DNA than current Cas9 tools can. That power could be put to work in genetic research to understand the underpinnings of disease — and potentially in treatment for diseases tied to long stretches of DNA.
Yan Zhang, Ph.D., the University of Michigan scientist who led the research, explains that the new tool harnesses a different type of CRISPR system than the Cas9-containing ones that are widely used. Both are borrowed from bacteria, where they normally function to find and weed out invading DNA.
A different type of CRISPR
The new tool uses a Type I CRISPR, which is much more common in bacteria than the Type II variety that includes Cas9. A Type I CRISPR has never been used in any eukaryotic cells and employs a riboprotein complex known as Cascade for seeking its target and an enzyme called Cas3 for shredding DNA.
The challenging protein optimization and purification side of the work was done in the laboratory of Cornell University professor Ailong Ke, Ph.D., a co-corresponding author of the paper. Cornell graduate student Adam Dolan and U-M senior research specialist Zhonggang Hou, Ph.D., are the paper’s first authors.
The research involved a long shot by Zhang, who has studied bacterial CRISPR-Cas9 and developed tools for editing genetic material in human cells, and Ke, who has studied Type I CRISPR using structural and biochemical approaches.
They set out to try to deliver the bacterial CRISPR components as proteins into both human embryonic stem cells and another type of cell called HAP1. With one CRISPR guide, the team succeeded in deleting portions of targeted DNA ranging from a few hundred base pairs to 100 kilobases.
A motorized shredder
Zhang calls the CRISPR-Cas3 system a “DNA shredder with a motor” because it can move along a DNA genome for a certain distance, breaking up the genetic material as it goes.
“Cas9 is a molecular scissor that goes where you want it and snips once,” says Zhang, an assistant professor of biological chemistry at the U-M Medical School. “But Cas3 goes where you want it, travels along the chromosome and makes a spectrum of deletions tens of kilobases long. This could make it a powerful screening tool to determine what large areas of DNA are most important for a particular disease.”
This could be especially useful when scientists are studying the “noncoding” long stretches of DNA that don’t contain the code for a particular protein; the “shredder” technique could allow them to demolish a sequence of long stretches and see what happens.
In addition, the ability of Cas3 to travel on the chromosome over a long distance can’t be done with any current Cas9 technique. So a “nuclease dead” version of Cas3 that can travel along DNA but lacks the shredder function might provide a powerful delivery platform for long-range epigenome engineering.
Part of the research effort involved figuring out how to get the human stem cells to reveal if any DNA had been deleted, since most of the stem cell “reporter” lines developed for research involving CRISPR-Cas9 are not sensitive enough if the shredding activity is low.
This new tool and its derivatives could be useful for therapeutic purposes, Zhang speculates, though such use is years in the future.
Some CRISPR-Cas9-based therapeutic uses have been reported — including a controversial editing out of a receptor gene that enables HIV to enter cells in the embryos of two babies reportedly born in China. But worries about CRISPR-Cas9 making unintended edits in normal areas of human patients’ DNA have also surfaced. Further work will be needed to see if the “shredder” approach avoids this issue.
By Kara Gavin
This content was originally posted by the University of Michigan.